Sentiment Rocker... Sentiment.... It is BAD overall for gloves... Vaccine news will NOT go away for another month... I think. Fundamentally, gloves are still very strong and looking forward there is no business as profitable and solid as gloves for 2021.
UAE says Sinopharm vaccine has 86% efficacy against COVID-19
DUBAI (Reuters) - An experimental coronavirus vaccine developed by China’s Sinopharm has 86% efficacy against the virus, the United Arab Emirates health ministry said on Wednesday, citing an interim analysis of a human trial underway there.
The Gulf Arab state in July started Phase 3 clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG). In September, the UAE approved its emergency use for certain groups.
The analysis also shows “99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease”, the ministry said in a statement carried by the state news agency.
“The analysis shows no serious safety concerns,” it said.
It also said it had officially registered the vaccine, without elaborating, and that 31,000 volunteers across 125 nationalities participated in the UAE trial.
@liquidity..I will also stop looking. This will eat me inside. It is only paper lost now. Fundamentals are still there and it will come back after all the vaccine hype is over. The reality of current situations are still the same for the recovery stocks. Nothing change fundamentally and it will take 2-3 years to get back to normal.
Posted by Morpheus61 at Dec 9, 2020 6:11 PM | Report Abuse Calling on anyone reading this, please understand that the backbone of any economy is the common man. If you take away the ability of the common man to contribute to the economic activity of the nation, the economy will sink over time. You will see joblessness, poverty, hunger and everythuing that we and our founding fathers hoped will never come to pass.
BOYCOTT ALL BANKS, INVESTMENT BANKS THAT ISSUE STRUCTURED WARRANTS
Today Top Glove released its 1QFY2021 report. You can access the full report here.
The stock has been trading at below RM7 level for the better part of the last few weeks on a myriad of news perceived as bad. Albeit all that, the company posted a net profit of RM2.38 billion for the quarter. They have approximately 8.2 billion outstanding shares. This gives the company an EPS of RM0.29 for the quarter. Let's do a bit of calculating:
- Assume the profits don't increase (they are expected to, but we will be conservative).
- This would mean an EPS of RM1.16 for FY2021.
- This translates into a forward P/E of 6 at price RM7 (as of writing this, the price is RM6.84)
This make is one of the lowest valued stocks in the entire stock market, with only 5 companies having forward P/Es of below 6 at the time of writing this.
If we assume that a stock is fairly priced at P/E 15, this would mean that the fair value of Top Glove is RM17.40.
At the same time, one of Top Glove's main competitors in the glove manufacturing market - Hartalega, has a consensus forward P/E of about 19.5 based on its current market price.
Let's assume that the market assigns the same valuation to Top Glove as it does to its direct competitor and simiarly-sized peer Hartalega. In this case, Top Glove's market price would be RM22.62.
United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19
TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided about the trial.
The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine.
The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided.
The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.”
The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization.
Got the last bullet... all in on Gloves... and Q to buy at 3.65. Could be another Sohai to buy at the BAD sentiment now. No risk No rewards. Still believe this to go to 5. Am I the only one here?
Hong Kong’s Ming Pao daily said in its editorial that there were grounds to believe that the UAE must have been stringent with the review and registration of the Chinese vaccine, given the country’s record of being transparent in its anti-virus policymaking and mass testing.
“The UAE also maintains sound ties with the West so sourcing vaccines from the United States or elsewhere should not be a grave challenge. If the Chinese vaccine is not safe or effective, there is no reason for the UAE to endorse Beijing’s vaccine propaganda and risk its own image and the health of its own people.
“Thus the UAE’s approval and its top leader’s injection of the SinoPharm vaccine have come as a much-needed vote of confidence that will help convince more countries. Diversified supply of vaccines, with viable alternatives from China, is key to ensuring fair and equitable access by poor countries,” said the op-ed.
SinoPharm revealed that senior officials in Egypt and Bahrain also took part in trials held there.
<<NPRA1985>> UAE is basically in deep economy problem. Hundreds of construction projects are in limbo while oil price is lackluster coupled with production cut and it has also lost huge revenue from trade, tourism and transportation. So, just take it with a pinch a salt what the so-called leaders are trying to do to save its economy.
By the way, local Emiratis only make up to about 11% of the total population. Mostly are expats.
And, UAE royals are indirectly involved in the 1MDB scandal i.e. IPIC.
There should not be any reason why FDA would not grant Emergency Use Authorization (EUA), as it is not meant for mass vaccination merely emergency use and that it is also optional unless there is/are significant setback(s). This would help to lift the morale (but not ease the actual number of cases) in this brutal winter which will probably see 10% of the population infected by the end of the winter and many hundred of thousands more people dying. This is also flu season in northern hemisphere.
Granting EUA is the least they can do for they are helpless against Covid coupled with flu season.
This has already priced-in thus negligible effect on Dow Jones. The news always has to come out with a headline to justify and recycle the reasons behind the Index up and down such as vaccine, unemployment, stimulus, etc until you believe that you can be a "qualified" economist too.
Trade using your own strategy and according to your emotion. Dow Jones or the market is directionless hovering around 30,000 probably till Biden take over in Jan. Unless you are day trader taking advantage of the swing, there is no point coming here on daily basis.
Bottom line is that Comfort is making higher and higher profit. Further, it is helping many countries to cope with Covid. Share appreciation is just a matter of time.
According to MARGMA, global demand is around 350 billion gloves and projected to increase around 10% annually. Whether they use glove for vaccination or not, it has minimal impact to the annual demand. Also, it is naive to assume they will vaccinate the whole world as many countries are poor and can't pay for roof over the head, while revaccination is quite likely required like flu-shot.
Personally, I hope we can put an end to this Covid so we can get back to normal life ASAP. Even my company is finishing up our book order from 2019, and hope to survive through 2021 with only a couple orders secured this year with super-low margin. Many big corporates including Petronas are trimming budget and deferring project(s), basically adopting a wait-and-see attitude. Present oil price up is not sustainable and artificially support by low production, thus O&G activities remain low throughout.
i tell u comfort ceo can eat shit lo!. most undervalue also no use. Tell u all my portfolio glowing green liao after dumping gloves. i hope everyone throw until this piece of stock back until 0.70 then buy wait for pandemic
Fact box: When and which Covid-19 vaccines are likely to be available in Asia
BEIJING/TOKYO/SEOUL/MANILA/TAIPEI/JAKARTA/DHAKA/HANOI (Dec 11): Trial data from Pfizer Inc with partner BioNTech SE, Moderna Inc and AstraZeneca Plc has shown their experimental vaccines are effective in preventing novel coronavirus infection. While regulatory processes are underway, few Asian countries expect to receive significant amounts of the vaccines initially. Here are estimated distribution time lines, supply deals announced and clinical trials being held in the region.
Australia The country has secured around 140 million doses: 53.8 million from AstraZeneca, 51 million from Novavax Inc, 10 million from Pfizer, and 25.5 million from distribution programme COVAX. It expects delivery of 3.8 million doses of AstraZeneca's vaccine in January and February next year and plans to begin inoculations in March.
China China has not announced supply deals with Western drugmakers, which instead have partnered with private companies in the country.AstraZeneca's vaccine may be approved in China by mid-2021 and its Chinese partner Shenzhen Kangtai Biological Products Co Ltd plans annual production capacity of at least 100 million doses by the end of this year. For the Pfizer/BioNTech vaccine, a unit of Shanghai Fosun Pharmaceutical Group Co Ltd plans a Phase II trial. Tibet Rhodiola Pharmaceutical Holding Co is bringing in Russian vaccine candidate Sputnik V and plans early and mid-stage trials in China. China has also approved three vaccine candidates developed by Sinovac Biotech Ltd and state-owned China National Pharmaceutical Group (Sinopharm) for emergency use, and Sinopharm hopes its two candidates will get conditional approval for general use this year.
Japan Japan has deals to buy 120 million doses from Pfizer/BioNTech in the first half of next year and 120 million from AstraZeneca - the first 30 million of which will be shipped by March 2021 - and 250 million from Novavax. It is also in talks with Johnson & Johnson and has a deal with Shionogi & Co Ltd. Experts said vaccine makers would need to conduct at least Phase I and II trials in Japan before seeking approval for use.
South Korea The country has deals to buy 20 million doses each from AstraZeneca, Pfizer and Moderna and another 4 million doses from Johnson & Johnson's Janssen, enough to cover up to 34 million people.It will procure additional doses for 10 million people through COVAX.Inoculation is likely to start in the second quarter of next year to allow time to observe possible side effects.
India The head of the Serum Institute of India, which makes the AstraZeneca vaccine, said on Nov. 23 the positive late-state trial result of the candidate will allow it to seek emergency use approval by year-end, before securing approval for full introduction by February or March. India also expects a government-backed vaccine to be launched as early as February. It is also conducting a late-stage trial of Sputnik V.
Taiwan Taiwan aims to secure around 15 million doses initially, both via the COVAX scheme and by direct purchases from manufacturers, and may buy an additional 15 million doses. The government has said it hopes to begin vaccinations in the first quarter next year.
Malaysia The Southeast Asian nation has agreed to buy 12.8 million doses of the Pfizer vaccine, becoming the first country in the region to announce a deal with the U.S. drugmaker after some expressed reservations over the need for the ultra-cold storage that the vaccine requires. Pfizer will deliver the first batch of 1 million doses in the first quarter of next year.
The Philippines The archipelago announced a deal on Nov. 27 for 2.6 million doses of the AstraZeneca vaccine and is discussing a possible 1 million more, covering about 1% of a population of 108 million people.It is also seeking 20 million to 50 million doses from Sinovac and is in talks with others, including Pfizer.Vaccine makers can seek approval from Philippine regulators even if no clinical trial is conducted in the country.
Indonesia Southeast Asia's most populous country has secured 125.5 million doses from Sinovac, 30 million from Novavax, is in talks with AstraZeneca and Pfizer to buy 50 million doses each, and expects to get 16 million from COVAX.Indonesia is testing Sinovac's vaccine and preparing mass vaccination for medical staff and other frontline workers to start as soon as late January.
Vietnam A government official said COVAX vaccines would cover only 20% of the population and the country is likely to have a chance to secure separate deals soon, as demand is very high.
Bangladesh Bangladesh signed a deal with India's Serum Institute to buy 30 million doses of the AstraZeneca vaccine.It also expects to receive 68 million doses from global vaccine alliance GAVI at a subsidised rate, a senior health ministry official said.
I also Q to buy at 3.5. Anyway, good time to add as I see this at 5 after all the hype on Recovery stocks are Over. Banks at all time high... like Pre Covid High... WTF. Recovery stocks are all RECOVERED. Economy has RECOVERED today. WTF.
Dannyfyl88 Sentiment Rocker... Sentiment.... It is BAD overall for gloves... Vaccine news will NOT go away for another month... I think. Fundamentally, gloves are still very strong and looking forward there is no business as profitable and solid as gloves for 2021.
Even so, the market does not seem to be working on logic and fundamentals, rather on sentiments. So, even profitable companies would continue to have low share prices, no? Could it be that, for the next year at least, that fundamentals no longer apply and people just run high on emotions?
New IPO: Building management systems (BMS), solar thermal systems and energy-saving services provider, Solar District Cooling Bhd aims to list on the Ace Market!
MQ Trader 505 views | 3 d ago
0:17
New IPO: The onshore and offshore support services provider for the O&G industry, Steel Hawk Bhd aims to list on the Ace Market!
MQ Trader 12622 views | 11 d ago
0:17
New IPO: The largest mini-market player and a leading groceries retailer in Malaysia, 99 Speed Mart Retail Holdings Bhd aims to list on the Main Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Dannyfyl88
1,215 posts
Posted by Dannyfyl88 > 2020-12-09 11:26 | Report Abuse
Sentiment Rocker... Sentiment.... It is BAD overall for gloves... Vaccine news will NOT go away for another month... I think. Fundamentally, gloves are still very strong and looking forward there is no business as profitable and solid as gloves for 2021.